Novartis AG (ADR) (NYSE:NVS)
Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
RTChokies
(94.59)
Submitted: 1/16/2012 10:01:04 AM :
Start Price:
$56.27
NVS Score:
-3.44
fair value is 71
Recs
Dan22italy
(43.45)
Submitted: 12/19/2011 1:00:13 AM :
Start Price:
$56.19
NVS Score:
-10.14
one of best pharma, good dividend
Recs
starbucks4ever
(99.03)
Submitted: 11/18/2011 2:07:58 AM :
Start Price:
$55.17
NVS Score:
-7.88
A reasonably safe bet. The management is finished destroying value through acquisitions: the last cash that remained to be squandered has been squandered last year, and during a debt crisis nobody will lend them money for the next purchase. That leaves us with a low PE, and with speculators assuming (mistakenly) that with no more empire building the "E" will finally accrue to them. This illusion will put a floor under the price, especially when the "E" is stable and speculators are desperately looking for stability.
Recs
MojoJoe
(22.48)
Submitted: 9/21/2011 11:34:38 AM :
Start Price:
$55.68
NVS Score:
-11.33
Excellent company, great dividend analysis.
Recs
clayman14
(93.47)
Submitted: 9/15/2011 4:30:29 PM :
Start Price:
$55.94
NVS Score:
-10.39
Swiss Compant + Decent Yield + Pharma
Recs
Ikarruss
(30.34)
Submitted: 9/6/2011 12:58:29 PM :
Start Price:
$55.52
NVS Score:
-14.99
Good company, makes generics, good ratios, has been delt up with europe, but is not in euro zone
Recs
Clint35
(68.01)
Submitted: 8/19/2011 1:46:31 AM :
Start Price:
$54.70
NVS Score:
-16.33
It's yielding 3.60%. Dividend growth has been good over the last 5 years. The P/E is only 13.11.
Recs
einzling44
(40.09)
Submitted: 8/10/2011 2:40:26 PM :
Start Price:
$55.14
NVS Score:
-14.34
Great management and an impressive product pipeline.
Recs
beadnell
(59.71)
Submitted: 8/4/2011 6:17:09 AM :
Start Price:
$59.07
NVS Score:
-12.95
It is a good day to buy European stocks (even cheaper than when I bought it.)
Recs
Jamanji
(27.03)
Submitted: 7/8/2011 10:36:44 AM :
Start Price:
$62.30
NVS Score:
-10.28
Barrons 7-4-11
Recs
utri
(< 20)
Submitted: 7/1/2011 11:44:37 AM :
Start Price:
$60.84
NVS Score:
-8.62
Has exposure to both patented and generic medicine.
Good balance sheet.
Should move up after Alcon acquisition is complete.
Recs
FuriousGreen
(57.12)
Submitted: 5/2/2011 2:20:51 PM :
Start Price:
$59.28
NVS Score:
-3.70
Solid in recession, solid outside of recession.
Recs
PsychoDr
(86.23)
Submitted: 4/22/2011 9:29:00 AM :
Start Price:
$57.03
NVS Score:
-1.98
One part of my health care triple play. Novartis is a pharmaceutical company with a nice dividend, international reach, and generic drug presence. Generics are the wave of the future and any company that can provide lower price medication for an emerging international market community is a strong long term play. Health care will see significant growth going forward, I want in on all aspects of the industry.
Recs
Greenesthorn
(44.61)
Submitted: 4/16/2011 6:33:54 PM :
Start Price:
$54.60
NVS Score:
+0.04
Good fundamentals, new FDA approvals
Recs
jtothes
(93.77)
Submitted: 4/14/2011 10:29:13 AM :
Start Price:
$55.63
NVS Score:
-1.43
Undervalued? Maybe, but with some new FDA approvals there should be ample opportunity for growth
Recs
Recs
healthcarevalue
(96.65)
Submitted: 3/9/2011 12:55:59 PM :
Start Price:
$55.26
NVS Score:
+0.26
NVS, Novartis, 119, 418 employees, based in Basel, Switzerland. Debt/equity of 0.36, market cap of 126.26 billion, relatively low price/earnings ratio as compared to others in industry, of 12.95. Diversified interests include vaccines, infectious disease treatment, and specifically, over-the-counter (OTC) drugs, animal health, and vision products.
Recs
alienbrett
(< 20)
Submitted: 2/26/2011 12:29:49 PM :
Start Price:
$56.06
NVS Score:
+0.84
Novartis is just a tad bit over valued, and soon, it will be realized. But over a long term, it will greatly improve and skyrocket.
Recs
Odiseo
(< 20)
Submitted: 2/24/2011 3:13:23 PM :
Start Price:
$56.24
NVS Score:
-9.98
Good pipe line, good generic, stable Pharma. We will not stop buying medicine and NVS will not stop selling. At some point they will com put ahead.
Recs
KempInTheWoods
(65.16)
Submitted: 2/10/2011 8:28:49 PM :
Start Price:
$53.73
NVS Score:
+2.67
Been fence sitting for some time. Seems undervalued for what it is. Well run Swiss healthcare with 60% of sales outside Europe. Wide range of drugs and tools.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 205 : 1 2 3 4 5 6 7 8 9 10 Next »